Flexibility to help meet
your patients' needs1


Quarterly or Monthly1

AJOVY® is the only licensed anti-CGRP treatment that offers the choice between quarterly and monthly dosing, with the option to switch between the two

CGRP, calcitonin gene-related peptide.


AJOVY® may be self administered1

Patients may self-administer AJOVY® if instructed in subcutaneous self-injection technique by a healthcare professional


Alone and in combination1

In Phase III trials, more than 20% of enrolled patients were taking an oral concomitant preventive medication

Suggestions to explore next

Continue to Adminstration page of AJOVY

Can be administered at home or in the clinic1

Administering ajovy®
Continue to Efficacy page of AJOVY

Significantly more migraine-free days with AJOVY® vs placebo1-3

Clinical trial data for AJOVY®

Better quality of life with AJOVY® vs placebo2,3

Quality of life data for ajovy®